Dr. Ulrica Sehlstedt

Managing Partner

Board of directors

Global Practice Leader, Healthcare & Life Sciences

Sweden

Ulrica brings over 20 years of broad-sector experience to serving clients across the entire healthcare and life science ecosystem.

Education

Stockholm University
PhD Biophysics
Chalmers University of Technology
M.Sc. Chemical Engineering

Past Experience

LightUp Technologies AB
CEO

Ulrica is a Partner in Arthur D. Little’s Stockholm office and heads the Global Healthcare and Life Sciences Practice.

Her work includes strategy development, opportunity assessment, complex procurement, operational & commercial due diligence, change management, and program management, for healthcare suppliers (pharma, Medtech, and biotech companies), providers (public and private), and investors.

Ulrica is passionate about the role of life science research and development as a lever for prosperity and health. 

Before joining Arthur D. Little in 2007, Ulrica spent seven years as CEO of a molecular diagnostics start-up. She has also been a member of the Swedish Research Council’s Scientific Council for Medicine for six years, and served as a Member of the 2007 and 2016 national expert panels in Life Science Technologies for Future Research Leaders, a program launched by the Swedish Foundation for Strategic Research. 

The brave new world of synthetic biology
The brave new world of synthetic biology
Major impacts, significant challenges
Time to renew your pilot’s license?
Time to renew your pilot’s license?
Five technologies board members and CEOs must keep on their radar screens
Tomorrow’s life sciences
Tomorrow’s life sciences
Insights. Impacts. Imperatives.
COVID-19 – FOCUSING ATTENTION ON THE NEXT TRANSFORMATION IN HEALTHCARE
Essentially the pandemic has shown the strengths and weaknesses of the global healthcare sector – and the opportunities that exist for improvement and transformation. While demonstrating what can be achieved through global collaboration, COVID-19 has also shone a harsh light on the disparities in healthcare access between developed and developing countries.
Hyper-collaboration in the healthcare and life science industry – The new imperative
The COVID-19 pandemic demonstrated the ability of the healthcare and life science industry to respond to unexpected needs with unprecedented speed. However, independent of the pandemic, the industry was already facing transformation in light of multiple, highly disruptive innovations not only in the traditional field of drug modalities but also in related fields such as digital, AI, data, and medical devices.

Ulrica is a Partner in Arthur D. Little’s Stockholm office and heads the Global Healthcare and Life Sciences Practice.

Her work includes strategy development, opportunity assessment, complex procurement, operational & commercial due diligence, change management, and program management, for healthcare suppliers (pharma, Medtech, and biotech companies), providers (public and private), and investors.

Ulrica is passionate about the role of life science research and development as a lever for prosperity and health. 

Before joining Arthur D. Little in 2007, Ulrica spent seven years as CEO of a molecular diagnostics start-up. She has also been a member of the Swedish Research Council’s Scientific Council for Medicine for six years, and served as a Member of the 2007 and 2016 national expert panels in Life Science Technologies for Future Research Leaders, a program launched by the Swedish Foundation for Strategic Research. 

The brave new world of synthetic biology
The brave new world of synthetic biology
Major impacts, significant challenges
Time to renew your pilot’s license?
Time to renew your pilot’s license?
Five technologies board members and CEOs must keep on their radar screens
Tomorrow’s life sciences
Tomorrow’s life sciences
Insights. Impacts. Imperatives.
COVID-19 – FOCUSING ATTENTION ON THE NEXT TRANSFORMATION IN HEALTHCARE
Essentially the pandemic has shown the strengths and weaknesses of the global healthcare sector – and the opportunities that exist for improvement and transformation. While demonstrating what can be achieved through global collaboration, COVID-19 has also shone a harsh light on the disparities in healthcare access between developed and developing countries.
Hyper-collaboration in the healthcare and life science industry – The new imperative
The COVID-19 pandemic demonstrated the ability of the healthcare and life science industry to respond to unexpected needs with unprecedented speed. However, independent of the pandemic, the industry was already facing transformation in light of multiple, highly disruptive innovations not only in the traditional field of drug modalities but also in related fields such as digital, AI, data, and medical devices.

More About Ulrica
  • Stockholm University
    PhD Biophysics
  • Chalmers University of Technology
    M.Sc. Chemical Engineering
  • LightUp Technologies AB
    CEO